Research indicates that based on East Asian NSCLC patients, immunotherapy targeting PD‐1/PD‐L1 exhibits suboptimal responses in EGFR mutant and ALK‐rearranged tumors while demonstrating improved responses in KRAS mutant tumors. This evidence concerns the gene KRAS and non-small cell lung carcinoma.